- Description
- Additional
Description
Details
Description:Mouse monoclonal antibody to human Transforming Growth Factor beta (TGF-β)
Purification: Protein G affinity purified
Product Type:Primary antibody
Target Protein:Human TGF-β
Immunogen:TGF-βfrom human platelets
Fusion Myeloma: Sp2/0-Ag14
Specificity:Western blotting demonstrated that this antibody reacts with the dimeric (25 kDa) and monomeric (12.5 kDa.) forms of TGF-β under both non-reducing and reducing conditions respectively. This antibody recognizes both human platelet-derived and recombinant TGF-β in ELISA.
Species Reactivity: Human, others not tested.
Host / Isotype: Mouse, IgG1 Kappa
Formulation: Lyophilized in 0.01M PBS, pH 7.0.
Reconstitution:Double distilled water is recommended and to adjust the final concentration to 1.00mg/mL.
Storage: Store at -20oC
Research Area:Growth Factors and Their Receptors, Angiogenesis
Background:
Transforming growth factor beta (TGF-β) has three isoforms (TGF-β1, TGF-β2, and TGF-β3) with similar functions.
The cytokine is a homodimer linked by disulfide bind. Inside cells, the cytokine forms a small latent complex with latent associated peptide (LAP). This small complex binds to latent TGF-β binding protein (LTBP) to be secreted to extra-cellular matrix. Disassociation of the latent proteins from TGF-β results in the release of the cytokine to its receptor. The process is called activation, which can be influenced by various factors, including proteases, metalloproteases, extreme pH, mild acidic condition, reactive oxygen species and integrins.
TGF-β is an anti-proliferation factor in normal cells. It increases the synthesis of p15 and p21, which can block the cyclin: CDK complex, and causes cells to stop at G1 phase. The cytokine can induce apoptosis through both SMAD and DAXX pathways. In cancer cells, TGF-β signaling is altered and TGF-β no longer stops cell proliferation.
Applications:
ELISA: The antibody reacts with TGF-β.
Western Blot: This antibody when used at concentration of 5-20ng/mL will allow visualization of 100ng/lane of TGF-β.
References:
If research is published using this product, please inform Anogen in order to cite the reference on this datasheet. Anogen will provide one unit of product in the same category as gratitude.
Additional
Additional Information
| Product Specificity | mAb anti-Human TGF-β, 2C5 |
|---|---|
| Application | EIA, WB |
| Size | 0.1 mg |
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
2.将构建完成的载体与慢病毒包装质粒混合,共转染靶细胞
3.收集病毒液
4.用病毒液感染靶细胞
5.用载体上带的抗生素进行筛选,如果没有,可以用无限稀释法
6.获得稳转株
然后你得确定，这个细胞株对于你得研究来说不可或缺，具有明确的代表性。
上面两个都没有问题的话，祝你顺利。
1.将外源基因插入慢病毒载体
2.将构建完成的载体与慢病毒包装质粒混合，共转染靶细胞
3.收集病毒液
4.用病毒液感染靶细胞
5.用载体上带的抗生素进行筛选，如果没有，可以用无限稀释法
6.获得稳转株
如果经费充足的话可以找公司包装病毒，如武汉的普健可以提供各种载体的构建及细胞株构建的技术服务。
由于质粒的不兼容性,拥有同种复制子的质粒不能在同一细胞内稳定共存,经过几代的复制,会质粒丢失,所以并不是任何两个或两个以上质粒都可以在同一细胞内稳定存在,但是可以同时进入.
稳定转染的细胞株，就是转染后质粒可以稳定整合到基因组上不会因细胞分裂而丢失。区别于质粒瞬时转染不能长时间保留质粒在细胞里。
